Navigation Links
Logical Therapeutics Secures $16.9M Series C Financing Round
Date:5/26/2010

Lead Candidate, LT-NS001, Shows Evidence of Improved GI Safety for Arthritis Patients

WALTHAM, Mass., May 26 /PRNewswire/ -- Logical Therapeutics, Inc., a private, clinical stage biopharmaceutical company, announced today it had closed on a $16.9 million Series C equity financing.  The round was led by existing investor SV Life Sciences, and included Burrill & Company, Novo A/S and Novitas Capital.

Logical Therapeutics is developing a family of new chemical entities using its patented Bio-activated Technology.TM The proprietary platform, which modifies the chemical structure of NSAIDs (non-steroidal anti-inflammatory drugs), is being developed to significantly reduce the gastrointestinal (GI) side effects often associated with NSAIDs.  The Company's lead compound, LT-NS001 (naproxen etemesil), is currently being studied in a Phase 2b/3 study comparing the cumulative rate of gastric ulcers vs. Naprosyn® in osteoarthritis patients after 12 weeks of treatment.  Completion of the study is expected in late 2010.

The Series C financing round is expected to provide sufficient capital to advance the Company's development program through further clinical and non-clinical activities necessary for registration. The Company intends to seek a business partner prior to commercialization.  

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics, Inc. is a venture-backed, privately held biopharmaceutical company focused on the development of bio-activated prodrugs to treat inflammatory conditions such as osteoarthritis and rheumatoid arthritis.  The Company's Bio-activated TechnologyTM has created a portfolio of molecules including LT-NS001, a naproxen prodrug and several additional bio-activated NSAID prodrug candidates, which are covered by issued and pending U.S. and international patents.  Each program addresses unmet medical needs in multi-billion dollar markets.  For more information about Logical Therapeutics, visit the Company's website at www.logicaltx.com.

LT-NS001 is an investigational drug product candidate undergoing clinical evaluation and has not been approved by the U.S. Food and Drug Administration.

Bio-activated TechnologyTM is a trademark of Logical Therapeutics, Inc.


'/>"/>
SOURCE Logical Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Neurobiological Technologies Announces Filing of Certificate of Dissolution and Closing of Stock Transfer Books
4. Tuesday, Dec. 1: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
5. Bayer HealthCare Pharmaceuticals Initiates Phase III Trial with Florbetaben PET Tracer for Imaging of Cerebral beta-Amyloid Plaques, a Pathological Hallmark of Alzheimers Disease
6. Monday, Nov. 30: News From the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) in Chicago
7. Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago
8. China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits
9. Neurobiological Technologies Announces Extraordinary Dividend of $0.18 per Share
10. Reportlinker Adds Audiological Devices - Global Market Trends
11. EntreMeds ENMD-2076 Active in Solid and Hematological Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
(Date:5/3/2016)...  Specialty Silicone Fabricators is offering teachers a ... cleanroom works. The free visual aid provides a ... Chris Mazelin , SSF ... enthusiastically supports the Science, Technology, Engineering and Math ... generation of innovators. We want to provide resources ...
(Date:5/3/2016)... , May 3, 2016 ... heute bekannt, dass sie einen entscheidenden Meilenstein ... haben: Ein Aufruf zum Handeln, um Patientenresultate ... Veröffentlichung trägt zu Fortschritten im Verständnis der ... hervor, ein Bewusstsein für Hepatische Enzephalopathie in ...
Breaking Medicine Technology:
(Date:5/3/2016)... (PRWEB) , ... May 04, 2016 , ... ... for cancer. That message is reaching the global health community through expanding activities ... the burden of cancer in the resource-limited countries. , In support ...
(Date:5/3/2016)... ... May 03, 2016 , ... In April, Amerec launched a new website ... help find the best steam and sauna solutions. , First, the Amerec website has ... improvement brings all of the site’s features, especially the Steam Builder Tool , ...
(Date:5/3/2016)... ... May 03, 2016 , ... For over 23 years, ... providers to build the leading network of doctors and therapists treating personal injury patients ... of the distinguished Bay Chiropractic and Rehabilitation in Santa Monica, Doctors on ...
(Date:5/3/2016)... (PRWEB) , ... May 03, 2016 , ... Registration is now open for the 31st ... 5, 2016 at the Hatch Memorial Shell on the Esplanade. The event regularly draws thousands ... 5K Run is a competitive, timed event fully sanctioned by the USA Track & Field ...
(Date:5/3/2016)... Santa Monica, California (PRWEB) , ... May 03, 2016 , ... ... cosmetic surgery practice in late 2014, incorporating the injectable filler into his menu ... journeys of aesthetic transformation. Now, more than a year later, he’s still improving his ...
Breaking Medicine News(10 mins):